Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Richard, Hafner"'
Autor:
Yu-Hong Liu, Shu Chen, Jing-Tao Gao, Yao Zhang, Kimberly Booher, Xiao-Fen Ding, Wei Shu, Jian Du, Jing Bao, Richard Hafner, Carol D. Hamilton, Liang Li
Publikováno v:
Infectious Diseases of Poverty, Vol 9, Iss 1, Pp 1-7 (2020)
Abstract Background With the second largest tuberculosis (TB) burden globally, China is committed to actively engage in international TB clinical trials to contribute to global TB research. However, lack of research capacity among local sites has bee
Externí odkaz:
https://doaj.org/article/b6249398be254af1a1d14427d11163f4
Autor:
Andreas Diacon, ProfPhD, Sachiko Miyahara, PhD, Rodney Dawson, PhD, Xin Sun, PhD, Evelyn Hogg, Kathleen Donahue, MA, Michael Urbanowski, PhD, Veronique De Jager, MD, Courtney V Fletcher, ProfPharmD, Richard Hafner, MD, Susan Swindells, ProfMBBS, William Bishai, ProfMD
Publikováno v:
The Lancet Microbe, Vol 1, Iss 2, Pp e84-e92 (2020)
Summary: Background: Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial 2 days of tuberculosis treatment, but that the activity of isoniazid declines substantially after day 3 of treatment. In this 14-day,
Externí odkaz:
https://doaj.org/article/18657402e09d414b9438792656058339
Autor:
Kamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, Richard Court, Xin Sun, Laura Moran, Richard Hafner, Lubbe Wiesner, Susan L Rosenkranz, Veronique de Jager, Nihal de Vries, Joseph Harding, Tawanda Gumbo, Susan Swindells, Andreas Diacon, Kelly E Dooley, Helen McIlleron, Paolo Denti
Publikováno v:
J Antimicrob Chemother
Background The WHO-endorsed shorter-course regimen for MDR-TB includes high-dose isoniazid. The pharmacokinetics of high-dose isoniazid within MDR-TB regimens has not been well described. Objectives To characterize isoniazid pharmacokinetics at 5–1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b8dc0ecf8f362cad586566bb49858b3
https://doi.org/10.1093/jac/dkac188
https://doi.org/10.1093/jac/dkac188
Autor:
Laura Moran, Elisa H. Ignatius, Susan Swindells, Paolo Denti, Richard Hafner, Florian von Groote-Bidlingmaier, Eric L. Nuermberger, Naadira Vanker, Soyeon Kim, Andreas H. Diacon, Kathleen Donahue, Kelly E. Dooley, Susan L. Rosenkranz, Kamunkhwala Gausi, Xin Sun, Lubbe Wiesner
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 204:1327-1335
Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b833f94aad7866bee81175a95aca777
https://doi.org/10.1164/rccm.202103-0534oc
https://doi.org/10.1164/rccm.202103-0534oc
Autor:
Robert N. Mahon, Richard Hafner
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
To meet the challenges of increasing antimicrobial resistance, the infectious disease community needs innovative therapeutics. Precision medicine and immunotherapies are transforming cancer therapeutics by targeting the regulatory signaling pathways
Externí odkaz:
https://doaj.org/article/f10ebfa90dad4c288760e20f3734e75f
Autor:
Lakshmi Jayashankar, Richard Hafner
Publikováno v:
Frontiers in Immunology, Vol 7 (2016)
Tuberculosis remains a global health threat of alarming proportions, resulting in 1.5 million deaths worldwide. The only available licensed vaccine, BCG, does not confer lifelong protection against active TB. To date, development of an effective vacc
Externí odkaz:
https://doaj.org/article/ac79b21d3b914b9f953201e1c202e711
Autor:
Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L. Rosenkranz, Elisa H. Ignatius, Eric L. Nuermberger, Laura Moran, Kathleen Donahue, Susan Swindells, Naadira Vanker, Andreas H. Diacon, Rachel Issa, Christopher Lane, Mark Lojacono, Rachel Mahachi, William Murtaugh, Lynette Purdue, Akbar Shahkolahi, Ronald Ssenyonga
Publikováno v:
Am J Respir Crit Care Med
Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to efficacy against T...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe528d97e300df90396f32ea97053c45
https://doi.org/10.1164/rccm.201910-1960oc
https://doi.org/10.1164/rccm.201910-1960oc
Autor:
Robert N. Mahon, Shabaana A. Khader, Richard Hafner, Jay A. Berzofsky, Ulrich E. Schaible, Suzanne Ostrand-Rosenberg, Gerhard Walzl, Nelita du Plessis, William R. Bishai, Yongjun Sui, Stefan H. E. Kaufmann, Manfred B. Lutz, Dmitry I. Gabrilovich, Ankita Garg, Anca Dorhoi, Leigh A. Kotze
Publikováno v:
J Clin Invest
The critical role of suppressive myeloid cells in immune regulation has come to the forefront in cancer research, with myeloid-derived suppressor cells (MDSCs) as a main oncology immunotherapeutic target. Recent improvement and standardization of cri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38929d369bb7ddec97e0fab37ad20812
https://doi.org/10.1172/jci136288
https://doi.org/10.1172/jci136288
Autor:
Eric L. Nuermberger, Karl-Dimiter Bissig, Larisa Y. Poluektova, Janice J. Endsley, Rajen Koshy, Selvakumar Subbian, Brendan K. Podell, Katrin Eichelberg, Angela Wahl, Petros C. Karakousis, Ramesh Akkina, Brigitte E. Sanders-Beer, Stephan Menne, Moses T. Bility, Daniel L. Barber, J. Victor Garcia, Alexander Ploss, Benjamin J. Burwitz, Richard Hafner, Brent E. Korba, Chris Lambros
Publikováno v:
Current HIV Research
The main advantage of animal models of infectious diseases over in vitro studies is the gain in the understanding of the complex dynamics between the immune system and the pathogen. While small animal models have practical advantages over large anima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8bc74796179c5f6ecfe05916d1e53ba
https://doi.org/10.2174/1570162x18666191223114019
https://doi.org/10.2174/1570162x18666191223114019
Autor:
Ashley N. Brown, George L. Drusano, Jonathan R. Adams, Jaime L. Rodriquez, Kalyani Jambunathan, Dodge L. Baluya, David L. Brown, Awewura Kwara, Jon C. Mirsalis, Richard Hafner, Arnold Louie
Publikováno v:
mBio, Vol 6, Iss 6 (2015)
ABSTRACT Linezolid is an oxazolidinone with potent activity against Mycobacterium tuberculosis. Linezolid toxicity in patients correlates with the dose and duration of therapy. These toxicities are attributable to the inhibition of mitochondrial prot
Externí odkaz:
https://doaj.org/article/0a8207688af7408c9f377cb7543d327b